Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG

Phase 2 Unknown 21 enrolled University Hospital, Essen GWT-TUD GmbH · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

IMAGINE is a Phase II, randomized, two-arm, chemotherapy controlled modular trial in subjects with histologically confirmed, resectable gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction (AEG). Up to 22 patients will be included in each arm of the trial.

Timeline

Start: 2019-09-26
Primary completion: 2024-03
Completion: 2025-06-01

Publications

Klute KA, Shah MA. Evolving Therapeutics for Resectable Esophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257044. doi: 10.6004/jnccn.2025.7044.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	480 mg	Intravenous
Subject	Relatlimab	Monoclonal antibody	80 mg	Intravenous
Background	Docetaxel	Small molecule	50 mg/m2	Intravenous
Background	Leucovorin	Small molecule	200 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	fluorouracil	Small molecule	2600 mg/m2	Intravenous

Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG

Summary

Timeline

Publications

Drugs

Indications